Synthetic biology startups are attracting venture funding in record amounts, with $1.9 billion making 2018 the largest year ever – and that’s only counting deals closed by early August. Even with more almost five months left in 2018, this represents 73% growth over 2017. As in the last four years, half or more of the funding went to later-stage (more mature) companies. The exceptional year of 2017 saw a drop in funding amount, but a sharp rise in the number of companies funded (56, compared to 48 in the previous year). Thus we see mature synbio companies continuing on an expansion trajectory, while a new wave of early-stage startups promises continued growth and innovation in the future.1
Click here to join our weekly newsletter. We want to hear what you think about this article. Got a tip for our news team? Write to firstname.lastname@example.org.